Immunological gene therapy with ex vivo gene-modified tumor cells: A critique and a reappraisal

Human Gene Therapy

Volumn 11, Issue 9, 2000, Pages 1269-1275

  Parmiani, Giorgio ^a   Rodolfo, Monica ^a   Melani, Cecilia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 2; VACCINE;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CYTOKINE RELEASE; DNA MODIFICATION; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; REVIEW; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD80; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; CYTOKINES; GENE THERAPY; HUMANS; INTERLEUKIN-12; INTERLEUKIN-2; ISOANTIGENS; MICE; NEOPLASMS; TRANSDUCTION, GENETIC; VACCINES, DNA;

EID: 0034631328     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050032375     Document Type: Review

References (50)

1. ALLIONE, A., CONSALVO, M., NANNI, P., LOLLINI, P.L., CAVALLO, F., GIOVARELLI, M., FORNI, M., GULINO, A., COLOMBO, M.P., DELLABONA, P., HOCK, H., BLANKESTEIN, T., ROSENTHAL, F.M., GANSBACHER, B., COLOMBO, M.C., MUSSO, T., GUSELLA, L., and FORNI, G. (1994). Immunizing and curative potential of replicating and non-replicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, TNF-alfa, GM-CSF, and IFN-gamma gene or admixed with conventional adjuvants. Cancer Res. 54, 6022-6026.
2. ANICHINI, A., MOLLA, A., MORTARINI, R., TRAGNI, G., BERSANI, I., DI NICOLA, M., GIANNI, M., PILOTTI, S., DUNBAR, R., CERUNDOLO, V., and PARMIANI, G. (1999). An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTL, but does not overcome tumor escape from immune surveillance in metastatic lesions. J. Exp. Med. 190, 651-668.
3. ARIENTI, F., SULÉ-SUSO, J., MELANI, C., MACCALLI, C., BELLI, F., ILLENI, M.T., ANICHINI, A., CASCINELLI, N., COLOMBO, M.P., and PARMIANI, G. (1994). Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. Hum. Gene Ther. 5, 1139-1150.
4. ARIENTI, F., SULÉ-SUSO, J., BELLI, F., MASCHERONI, L., RIVOLTINI, L., MELANI, C., MAIO, M., CASCINELLI, N., COLOMBO, M.P., and PARMIANI, G. (1996). Limited anti-tumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum. Gene Ther. 7, 1955-1963.
5. ARIENTI, F., BELLI, F., NAPOLITANO, F., SULÉ-SUSO, J., MAZZOCCHI, A., GALLINO, G.F., CATTELAN, A., SANANTONIO, C., RIVOLTINI, L., MELANI, C., COLOMBO, M.P., CASCINELLI, N., MAIO, M., and PARMIANI, G. (1999). Vaccination of melanoma patients with interleukin 4 gene transduced allogeneic melanoma cells. Hum. Gene Ther. 10, 2907-2916.
6. BASOMBRIO, M.A. (1970). Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene. Cancer Res. 30, 2458-2462.
7. BOWMAN, L.C., GROSSMAN, M., RILL, D., BROWN, M., ZHONG, W.-Y., ALEXANDER, B., LEIMING, T., COUSTAN-SMITH, E., CAMPANA, D., JENKINS, J., WOODS, D., and BRENNER, M. (1998a). Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum. Gene Ther. 9, 1303-1311.
8. BOWMAN, L., GROSSMAN, M., RILL, D., BROWN, M., ZHONG, W.Y., ALEXANDER, B., LEIMIG, T., COUSTAN-SMITH, E., CAMPANA, D., JENKINS, J., WOODS, D., KITCHINGMAN, G., VANON, E., and BRENNER, M. (1998b). IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 92, 1941-1949.
9. BUBENIK, J., VOITENOK, N.N., KIELER, J., PRASSOLOV, V.S., CHUMAKOV, P.M., BUBENIKOVA, D., SIMOVA, J., and JANDLOVA, T. (1988). Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol. Lett. 19, 279-282.
10. CAVALLO, F., SIGNORELLI, P., GIOVARELLI, M., MUSIANI, P., MODESTI, A., BRINDA, M.J., COLOMBO, M.P., and FORNI, G. (1997). Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J. Natl. Cancer Inst. 89, 1049-1058.
11. COLOMBO, M.P., and FORNI, G. (1994). Cytokine gene transfer in tumor inhibition and tentative tumor therapy: Where are we now? Immunol. Today 15, 48-51.
12. COLOMBO, M.P., and RODOLFO, M. (1995). Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: Do animal studies really support clinical trials? Cancer Immunol. Immunother. 41, 265-270.
13. CROWLEY, N.J., SLINGLUFF, C.L., JR., DARROW, T.L., and SEIGLER, H.F. (1990). Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogenic melanomas. Cancer Res. 50, 492-498.
14. DEL VECCHIO, M., and PARMIANI, G. (1999). Cancer vaccination. Forum Trends Exp. Clin. Med. 9, 239-256.
15. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOLL, D., and MULLIGAN, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulate potent, specific, and long lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90, 3539-3543.
16. DUDLEY, M.E., and ROOPENIAN, D.C. (1996). Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. J. Exp. Med. 184, 441-447.
17. DUNNION, D.J., CYWINSKI, A.L., TUCKER, V.C., MURRAY, A.K., RICKINSON, A.B., COULIE, P., and BROWNING, M.J. (1999). Human antigen-presenting cell/tumor cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro. Immunology 98, 541-550.
18. FORNI, G., and BOGGIO, K. (1999). Cytokine-gene engineered vaccines. Curr. Opin. Mol. Ther. 1, 34-38.
19. GÄKEN, J.A., HOLLINGSWORTH, S.J., HIRST, W.J., BUGGINS, A.G., GALEA-LAURI, J., PEAKMAN, M., KUIPER, M., PATEL, P., TOWNER, P., PATEL, P.M., COLLINS, M.K., MUFTI, G.J., FARZANEH, F., and DARLING, D.C. (1997). Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors. Hum. Gene Ther. 8, 477-488.
20. GARRIDO, F., RUIZ-CABELLO, F., CABRERA, T., PEREZ-VILLAR, J., LOPEZ-BOTET, M., DUGGAN,-KEEN, M., and STERN, P.L. (1997). Implications for immunosurveillance of altered HLA-class I phenotypes in human tumours. Immunol Today 18, 89-95.
21. HUANG, A.Y.C., GOLUMBEK, P., AHMADZADEH, M., JAFFEE, E., PARDOLL, D.M., and LEVITSKY, H. (1994). Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965.
22. IMRO, M.A., DELLABONA, P., MANICI, S., HELTAL, S., CONSOGNO, G., BELLONE, M., RUGARLI, C., and PROTTI, M.P. (1998). Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro. Hum. Gene Ther. 9, 1334-1335.
23. LANZAVECCHIA, A., IEZZI, G., and VIOLA, A. (1999). From TCR engagement to T cell activation: A kinetic view of T cell behavior. 96, 1-4.
24. MARCHAND, M., VAN BAREN, N., WEYNANTS, P., BRICHARD, V., DRENO, B., TESSIER, M.H., RANKIN, E., PARMIANI, G., ARIENTI, F., HUMBLET, Y., BOURLOND, A., VANWIJCK, R., LIENARD, D., BEAUDUIN, M., DIETRICH, P.Y., RUSSO, V., KERGER, J., MASUCCI, G., JAGER, E., DE GREVE, J., ATZPODIEN, J., BRASSEUR, R., COULIE, P.G., VAN DER BRUGGEN, P., and BOON, T. (1999). Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80, 219-230.
25. MAZZOCCHI, A., MELANI, C., RIVOLTINI, L., CASTELLI, C., LOMBARDO, C., COLOMBO, M.P., and PARMIANI, G. (2000). Transduction of both B7.1 and interleukin-2 genes into human melanoma cells to be used as vaccine: In vitro characterization of the transduced cell lines. (Submitted.)
26. MUSIANI, P., MODESTI, A., GIOVARELLI, M., CAVALLO, F., COLOMBO, M.P., LOLLINI, P.L., and FORNI, G. (1997). Cytokines, tumor cell death and immunogenicity: A question of choice. Immunol. Today 15, 48-51.
27. NESTLE, F.O., ALIJAGIC, S., GILLIET, M., SUN, Y., GRABBE, S., DUMMER, R., BURG, G., and SCHADENDORF, D. (1998). Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328-332.
28. PAILLARD, F. (1998). The search for the "best" cytokine to induce antitumor immunity. Hum. Gene Ther. 9, 2457-2458.
29. PARDOLL, D.M. (1995). Exposing the immunology of naked DNA vaccines. Immunity 3, 165-169.
30. PARMIANI, G. (1998). Editorial. Immunological approach to gene therapy of human cancer: Improvements through the understanding of mechanism(s). Gene Ther. 5, 863-864.
31. PARMIANI, G., COLOMBO, M.P., MELANI, C., and ARIENTI, F. (1997). Cytokine gene transduction in the immunotherapy of cancer. Adv. Pharmacol. 40, 259-307.
32. PARMIANI, G., ARIENTI, F., MELANI, C., BELLI, F., GALLINO, G., and MAZZOCCHI, A. (2000). Gene therapy of melanoma. In Melanoma: Methods and Protocols. B.J. Nickoloff, ed. (Humana Press, Totowa, NJ) in press.
33. PORGADOR, A., GANSBACHER, B., BANNERJI, R., TZEHOVAL, E., GILBOA, E., FELDMAN, M., and EISENBACH, L. (1993). Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int. J. Cancer 53, 471-477.
34. RIVOLTINI, L., SQUARCINA, P., LOFTUS, D.J., CASTELLI, C., TARSINI, P., MAZZOCCHI, A., RINI, F., VIGGIANO, V., BELLI, F., and PARMIANI, G. (1999). A superagonistic variant of peptide MART1/Melan A 27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: Implication for more effective immunotherapy. Cancer Res. 59, 301-306.
35. RODOLFO, M., ZILOCCHI, C., MELANI, C., VAGLIANI, M., CAPPETTI, B., ARIOLI, I., PARMIANI, G., and COLOMBO, M. (1996). Immunotherapy of experimental metastases by vaccination with interleukin gene transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J. Immunol. 157, 5536-5542.
36. ROMERO, P., DUNBAR, P.R., VALMORI, P.R., PITTET, M., OGG. G.S., RIMOLDI, D., CHEN, J.L., LIÉNARD, D., CEROTTINI, J.C., and CERUNDOLO, V. (1998). Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 9, 1641-1650.
37. ROSENBERG, S.A. (1997). Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18, 175-182.
38. ROSENBERG, S.A., YANG, J.C., SCHWARTZENTRUBER, D.J., HWU, P., MARINCOLA, F.M., TOPALIAN, S.L., RESTIFO, N.P., DUDLEY, M.E., SCHWARTZ, S.L., SPIESS, P.J., WUNDERLICH, J.R., PARKHURST, M.R., KAWAKAMI, Y., SEIPP, C.A., EINHIRN, J.H., and WHITE, D.E. (1998a). Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321-327.
39. ROSENBERG, S.A., ZHAI, Y., YANG, J.C., SCHWARTZENTRUBER, D.J., HWU, P., MARINCOLA, F.M., TOPALIAN, S.L., RESTIFO, N.P., SEIPP, C.A., EINHORN, J.H., ROBERTS, B., and WHITE, D.E. (1998B). Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 90, 1894-1900.
40. ROSSI, I., NICOLETTI, G., LANDUZZI, L., FRABETTI, F., DE GIOVANNI, C., NANNI, P., MUSIANI, P., FERRANTINI, M., BELARDELLI, F., and LOLLINI, P.-L. (1998). Inhibition of lung colonisation of a mouse mammary carcinoma by therapeutic vaccination with interferon-alpha gene-transduced tumor cells. Clin. Exp. Med. 16, 123-128.
41. ROTH, J.A., and CRISTIANO, R.J. (1997). Gene therapy for cancer: What have we done and where are we going? J. Natl. Cancer Inst. 88, 21-39.
42. SIMONS, J.W., and MIKHAK, B. (1998). Ex vivo gene therapy using cytokine-transduced tumor vaccines: Molecular and clinical pharmacology. Semin. Oncol. 25, 661-676.
43. SIMONS, J.W., MIKHAK, B., CHANG, J.-F., DE MARZO, A.M., CARDUCCI, M.A., LIM, M., WEBER, C.E., BACCALA, A.A., GOEMANN, M.A., CLIFT, S.M., ANDO, D.G., LEVITSKY, H.I., COHEN, L.K., SANDA, M.G., MULLIGAN, R.C., PARTIN, A.W., CARTER, H.B., PIANTADORSI, S., MARSHALL, F.F., and NELSON, W.G. (1999). Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate cells engineered to secrete granulocyte-macrophage colony stimulating factor using ex vivo gene transfer. Cancer Res. 59, 5160-5168.
44. SOBOL, R.E., and ROYSTON, I. (1995). Clinical Protocol. Injection of colon carcinoma patients with autologous irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2 (IL-2): A phase I study. Hum. Gene Ther. 6, 195-204.
45. SRIVASTAVA, P.K., MENORET, A., BASU, S., BINDER, R.J., and McQUADE, K.L. (1998). Heat shock proteins come of age: Primitive functions acquire new roles in an adaptive world. Immunity 8, 657-665.
46. TEPPER, R.L., PATTENGALE, K., and LEDER, P. (1989). Murine interleukin-4 displays a potent antitumor activity in vivo. Cell 57, 503-508.
47. THOMAS, M.C., GRETEN, T.F., PARDOLL, D.M., and JAFFEE, E.M. (1998). Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum. Gene Ther. 9, 835-843.
48. TOES, R.E.M., OSSENDORP, F., OFFRINGA, R., and MELIEF, C.J.M. (1999). CD4 T cells and their role in antitumor immune response. J. Exp. Med. 189, 753-756.
49. VAN DEN OORD, J., MAES, A., STAS, M., NUYTS, J., BATTOCCHIO, S., KASRAN, A., GARMYN, M., DE WEVER, I., and DE WOLF-PEETERS, C. (1996). CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am. J. Pathol. 149, 1953-1961.
50. ZATLOUKAL, K., SCHNEEBERG, A., BERGER, M., SCHMIDT, W., KOSZIK, F., KUTIL, R., COTTEN, M., WAGNER, E., BUSCHLE, M., MAASS, G., PAYER, E., STINGL, G., and BIRNSTIEL, M.L. (1995). Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. J. Immunol. 154, 3406-3419.